Abbott Laboratories (ABT)
| Market Cap | 151.56B -33.7% |
| Revenue (ttm) | 45.13B +6.6% |
| Net Income | 6.25B -53.5% |
| EPS | 3.57 -53.6% |
| Shares Out | 1.74B |
| PE Ratio | 24.17 |
| Forward PE | 15.40 |
| Dividend | $2.52 (2.90%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 6,310,831 |
| Open | 86.32 |
| Previous Close | 86.30 |
| Day's Range | 86.25 - 88.30 |
| 52-Week Range | 86.15 - 139.06 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 130.90 (+50.44%) |
| Earnings Date | Apr 16, 2026 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $130.9, which is an increase of 50.44% from the latest price.
News
Abbott removed from US Conviction List at Goldman Sachs
Goldman Sachs analysts removed Abbott (ABT) from the firm’s US Conviction List as part of its monthly update. Published first on TheFly – the ultimate source for real-time, market-moving breaking
Abbott receives FDA clearance and CE Mark for Ultreon imaging platform
Abbott (ABT) received FDA clearance and CE Mark for its Ultreon 3.0 Software. Ultreon 3.0 is an AI powered imaging platform that uses optical coherence tomography to give doctors real-time
Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform
Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery T...
Abbott announces new late-breaking data from four trials on PFA, CSP portfolios
Abbott (ABT) announced new late-breaking data from four trials that demonstrate “strong” clinical outcomes within its pulsed field ablation, PFA, and conduction system pacing, CSP, portfolios to treat...
Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month ...
3 ‘Strong Buy’ Dividend Aristocrat Stocks, 4/23/26
The article uses TipRanks’ Dividend Aristocrat tool to identify Abbott Laboratories ($ABT), Cintas ($CTAS), and Chevron ($CVX) as three dividend aristocrat stocks that have a ‘Strong Buy’ rating on Wa...
Abbott downgraded to Neutral from Outperform at Daiwa
Daiwa downgraded Abbott (ABT) to Neutral from Outperform with a price target of $92, down from $113. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial
Abbott price target lowered to $143 from $144 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Abbott (ABT) to $143 from $144 and keeps an Overweight rating on the shares. The firm views the company’s Q1
Abbott says data at AACR demonstrate advancements in Cancerguard test
Abbott (ABT) announced it will present new data at the American Association for Cancer Research Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early dete...
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical i...
Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings
Financial results barely beat Wall Street estimates.
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales
Abbott Laboratories cut its full-year earnings outlook to account for a recent acquisition and said a weaker-than-expected flu season hurt its recent quarter.
Abbott Laboratories Earnings Call Transcript: Q1 2026
Q1 results met expectations with 3.7% sales growth and $1.15 adjusted EPS, despite higher financing costs and a weak respiratory season. The Exact Sciences acquisition is integrating well, driving growth in cancer diagnostics, while medical devices and pharma segments delivered strong performances.
Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.
Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Abbott first-quarter results beat on cancer diagnostics, medical device strength
Abbott marginally beat Wall Street estimates for quarterly profit and revenue on Thursday, partially helped by its newly acquired cancer diagnostics business.
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncolog...
Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says
A jury in Chicago on Thursday said Abbott Laboratories must pay $53 million in compensatory damages to a group of families that had accused the company of failing to warn that its formula for prematur...
New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9...
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment...
Abbott hosts conference call for first-quarter earnings
ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ Learn more at Cologuard.com/TheTalk ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (N...
Abbott completes acquisition of Exact Sciences
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABB...
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions...
Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit
MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio, one of the world's leading innovative agtech companies, will be taking the stage at the World Agri-Tech Innovation Summit taking place March 16–18, 2026. Chris...
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 Improve...